INTRODUCTION
Actinic (solar) keratosis (AK) is a skin disease found in high prevalence in populations with fair skin as a result of significant, chronic exposure to ultraviolet radiation (UVR) [1] [2] [3] .
AK lesions are regarded as premalignant lesions that unpredictably can progress into squamous cell carcinoma (SCC), if left untreated. Although liquid nitrogen cryotherapy and surgical interventions are efficacious treatment options against individual AK lesions, well-tolerated and effective therapies treating the entire UV-induced field change with good cosmetic outcome are essential to ensure high sustained clearance and a good long-term outcome for the patient [4, 5] . Traditionally, 5-fluorouracil, imiquimod, and diclofenac are used in field therapy with treatment lengths over weeks or months with photodynamic therapy (PDT)
offering an alternative approach [4, 6] . Recently, ingenol mebutate gel (Picato Ò , LEO Pharma A/S) was introduced to the market for topical field treatment of AK in a contiguous skin area of approximately 25 cm 2 [7, 8] .
Ingenol mebutate (1) is a naturally occurring 3-monoester of ingenol (2) and angelic acid ( Fig. 1 ), which has been used in traditional medicine to treat various skin conditions. Ingenol mebutate can be isolated from the Euphorbia peplus (petty spurge) plant [9, 10] , but it can also be prepared by an efficient semisynthesis from the diterpene ingenol [11] . Topical treatment with ingenol mebutate gel for two or three consecutive days has been associated with high clearance rates, modest local skin responses and sustained clearance of AK lesions in patients at 1-year follow-up [12] . The clinical efficacy of ingenol mebutate against AK is believed to be linked to a dual mechanism of action, i.e., (1) induction of local cell death and (2) induction of a local immune response, which at least partially, is mediated by the activation of protein kinase C (PKC) [13] [14] [15] [16] .
The marketed ingenol mebutate gel needs to be refrigerated due to the limited chemical stability of ingenol mebutate and we have therefore been seeking more stable products with similar or improved in vitro potency and in vivo efficacy. We have previously published some of our efforts towards novel analogues of ingenol mebutate having improved physicochemical properties [17, 18] , such as chemical stability and preserved favorable in vitro pharmacological properties. Some key findings from the structure-activity studies should be pointed out: (1) methylation of the 5-or 20-hydroxyl groups in the rigid ingenol scaffold eliminated the biological effects, (2) ingenol itself lacks biological activity, (3) the carbonyl moiety of the ester groups is essential for biological effects and the activation of PKC, likely via an interaction with the Gly23 NH in the C1 domain, and (4) the 4-, 5-, and 20-hydroxyl groups form a framework for a pH-dependent acyl migration of the ester moiety leading to degradation of ingenol mebutate resulting in limited shelf life [17] . A recent study on a series of ingenol scaffold-modified cyclohexyl esters showed that complete removal of the 4-or 5-hydroxyl groups led to a moderate drop in activity, whereas removal of both hydroxyl groups resulted in a significant loss in activity [19] .
The chemical stability could be improved by having substituents flanking the ester group, but this often resulted in reduced potency [17, 18] . tert-Butylmethylether (400 mL) was added to the reaction mixture, and the organic layer was washed consecutively with water (4 9 100 mL), aqueous NaHCO 3 (100 mL) and water (3 9 100 mL) followed by drying over Na 2 
Compound Stability

Stability in Hydroalcoholic Gel
The marketed ingenol mebutate gel and ingenol disoxate hydroalcoholic gel of GMP quality were stored in 1 mL laminated tubes with screw caps. Concentration and impurity determinations for ingenol mebutate (triplicates) and ingenol disoxate (duplicates) were performed on Waters UHPLC equipment using external reference standards of ingenol mebutate (1) and ingenol disoxate (3), respectively.
Determination of ingenol mebutate was performed using a reverse phase UHPLC method with an Acquity UPLC BEH C18, 100 9 2.1 mm, sub 2 lm column and a mobile phase gradient of 0.1% phosphoric acid and acetonitrile, from 50% v/v to 90% v/v acetonitrile, and UV detection at 212 nm.
Ingenol disoxate was analyzed analogously using a reverse phase UHPLC method with an Acquity HSS C18, 150 9 2.1 mm, sub 2 lm column and the same mobile phases from 50% v/v to 95% v/v acetonitrile, and UV detection at 220 nm.
Preparation of Ingenol Disoxate Hydroalcoholic
Gel An aqueous citrate buffer with pH 2.8 was prepared by mixing water, citric acid monohydrate and sodium citrate dihydrate in the main production vessel. Ingenol disoxate (3) was dissolved in benzyl alcohol in a secondary vessel and isopropanol was added.
The ingenol disoxate alcoholic solution was added to the aqueous buffer at a temperature below 15°C. The gelling agent was slowly added to the hydroalcoholic solution and mixed until a homogeneous gel was formed. 
Preparation of the Analytical Samples
Stability in Phosphate Buffer
The stability of ingenol mebutate (1), ingenol disoxate (3) and the 5-and 20-isomers of ingenol disoxate (8, 9) was evaluated in phosphate buffer (0.067 M; pH 7.4) with 30% co-solvent (acetonitrile). An initial compound concentration of 100 lM was used and the stability was monitored at 37°C for a 24-h period on a Waters LCT Premier XE TOF instrument with Acquity UPLC. The products were separated using a reverse phase UPLC method with an Acquity HSS C18, 50 9 2.1 mm, 1.8 lm column and a linear gradient of 10 mM ammonium acetate and acetonitrile (both with 0.1% formic acid) from 1% v/v to 95% v/v acetonitrile in 2 min with a 0.7 mL/min flow rate. The relative recovery of the analytes was determined by UV detection (240-400 nm) and the identity of the degradation products was confirmed using positive mode MS electrospray detection and external reference standards. 
Acute Cancer Cell Cytotoxicity
Statistical Analysis
Statistical significance was evaluated using two-sample unpaired t test comparing the averages obtained in separate experiments.
Comparison of skin exposure levels in the Franz chamber diffusion set-up was performed using the Mann-Whitney U test. Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, Inc. La Jolla, CA, USA).
RESULTS
Regiocontrolled Syntheses of Ingenol Esters
Following our previously published stereoconservative semisynthetic method, ingenol mebutate (ingenol 3-angelate, 1) was prepared from ingenol (2) without concomitant isomerization of the angelate (Z-form) to the corresponding tiglate (E-form) [11] . Ingenol disoxate (3) was prepared by reacting the 5,20-acetonide protected ingenol derivative (5) with 3,5-diethylisoxazole-4-carbonyl chloride (4) with 4-dimethylaminopyridine as catalyst under microwave heating in an overall yield of 69% after deprotection (Fig. 2) . The potential rearrangement product 8 (Table 1) was synthesized by masking the 20-and 3-postions with t-butyldimethylsilyl (12) and trimethylsilyl (13) groups, respectively, prior to acylation with 3,5-diethylisoxazole-4-carbonyl chloride (4) followed by deprotection.
The other more stable 20-isomer 9 was made in a modest yield of 23% by a base-catalyzed rearrangement of ingenol disoxate in isopropanol.
Ingenol Mebutate and Ingenol Disoxate Have Comparable Lipophilicities
The distribution coefficients (logD) at pH 3 were determined by the shake flask method to be 3.5
for ingenol mebutate and 3.9 for ingenol disoxate. Due to the lipophilic character of the compounds in combination with their relatively weak UV response the quantification of the compounds in the buffer phase is associated with some degree of uncertainty.
The partition coefficients (S ? logP) were calculated to be 2.35 for ingenol mebutate and 2.24 for LEO ingenol disoxate.
Ingenol Disoxate is a Chemically Stable Ingenol Ester
The stability of ingenol disoxate hydroalcoholic gel 0.05% has been investigated at long term and accelerated storage conditions, 5°C and 25°C/60%RH, respectively ( Table 2 ). The concentration determinations of ingenol disoxate, calculated as percentage of label claim, are listed together with data for related impurities and pH of the gel in Table 2 .
Results show that the primary degradation product for ingenol disoxate in hydroalcoholic gel is 8 caused by acyl migration by the side chain from the 3-to the 5-position ( Table 2) .
Measurements of the amounts of ingenol disoxate show minimal fluctuations during the 18 months storage of the ingenol disoxate hydroalcoholic gel at 5°C. The accelerated conditions at 25°C/60%RH led to a decrease of 2.6% of label claim of ingenol disoxate after 6 months storage. The content of the primary degradation product 8 increased from 0.4% area to 2.0% area after 6 months storage at 25°C/ 60%RH. Some new minor impurities also started to appear. The stability of the marketed 0.05% ingenol mebutate gel has also been investigated at long term and accelerated storage conditions, 5°C
and 25°C/60%RH, respectively (Table 2) .
Results show that the primary degradation product in the ingenol mebutate gel is PEP 015 (6), as a result of acyl migration ( Table 2 ). The measured amounts of ingenol mebutate show some fluctuation and a tendency to decrease over time when the gel is stored at 5°C. The amount of ingenol mebutate in the gel shows a decrease of 8.0% of label claim after 6 months storage at 25°C/60%RH. The content of the primary degradation product 6 increased from 0.2% area to 5.1% area after 6 months storage at 25°C/60%RH.
To investigate the stability under conditions of further biological relevance we subjected ingenol disoxate to a test over 24 h in aqueous buffer (pH 7.4) at 37°C, while quantifying the relative amounts of ingenol disoxate and its potential rearrangement Step A: microwave assisted coupling with DMAP/DIPEA catalysis in acetonitrile, 150°C, 94% yield.
Step B: deprotection in aqueous hydrochloric acid at room temperature, 69% yield products 8 (5-isomer) and 9 (20-isomer; Fig. 3a) .
Ingenol disoxate (3) was slowly converted to the more stable inactive 20-isomer (9), which amounted to 1% and 25% at 2 and 24 h, respectively. The intermediate 5-isomer (8) remained at low (\3%) and relatively constant levels during the entire monitoring period. The corresponding study of ingenol mebutate stability showed a rapid conversion into the 5-isomer (6), which gradually rearranged into the thermodynamically more stable and inactive 20-isomer (7; Fig. 3b ). Following 2-and 24-h incubation, the remaining levels of Long-term stability of the marketed ingenol mebutate gel (0.05% w/v; pH 3.6-3.8) and ingenol disoxate in hydroalcoholic gel (0.05% w/v; pH 3.4-3.5) was investigated at 5°C and at accelerated storage conditions (25°C/60% relative humidity). The concentration determinations of ingenol disoxate and ingenol mebutate, calculated as percentage of label claim, are listed together with relative levels of impurities a, b Denote the 5-isomer re-arrangement products of ingenol disoxate (8) and ingenol mebutate (6), respectively ingenol mebutate amounted to approximately 60% and 45%, respectively. The conclusions regarding the relative stabilities were further supported by studies of the 20-isomer of ingenol disoxate (9) being the thermodynamically more stable product as it did not change over time (Fig. S1A in the supplementary material) . suggesting that the mechanism of cytotoxicity is similar [13, 20] . We sought to investigate if the cytotoxic potency was maintained by the novel ingenol mebutate analogue ingenol disoxate by analyzing acute cytotoxicity in the human epithelial cervix carcinoma cell line, HeLa, and in the human SCC line, HSC-5. The concentration required to decrease cell viability by 50% was significantly (twofold) lower for ingenol disoxate relative to ingenol mebutate demonstrating a significantly higher cytotoxic potency of ingenol disoxate (Fig. 4) .
Ingenol Disoxate is a Strong Activator of Classical and Novel PKC Isoforms
PKC is a family of serine/threonine kinases which can be divided into subgroups based on sensitivity to calcium ions and lipid modulators [21, 22] . Several findings suggest that part of the activity of ingenol mebutate involves spatio-temporal activation of both novel and classical PKC isoforms, leading to a pro-inflammatory response that may contribute to clinical efficacy of ingenol mebutate [14, 23] . Epidermal keratinocytes express both classical (a) and novel (d, g, e)
PKC isoforms [24] . [25, 26] . We set out to investigate if similar inhibitory effects on cell growth were induced by ingenol disoxate treatment. Following 3 days exposure we observed marked growth inhibition following either ingenol disoxate or ingenol mebutate exposure (Fig. 5 ).
Most notably, ingenol disoxate inhibited cell proliferation with an eightfold higher potency relative to ingenol mebutate with a half-maximal effect at 1.1 nM. Cell number [27, 28] .
To further explore the mechanism underlying the antiproliferative effect we investigated if treatment could impact keratinocyte differentiation. In the epidermis of healthy skin, keratinocytes proliferate in the basal layer but commit to terminal differentiation in response to a vertical calcium gradient as they move outwards through the supra-basal layers before forming the stratum corneum barrier. This strictly keratinocyte differentiation markers (Fig. 6 ).
These effects were abolished by pretreatment with bisindolylmaleimide-1; an inhibitor of novel and classical PKC isoforms. Induction of gene transcription was either on par with (INVL, TGM1) or significantly increased (FLG, LOR) relative to a calcium switch response where cells were grown in high calcium medium (1.8 mM CaCl 2 ) for 72 h. Transcript repression of early differentiation markers KRT1 and KRT10 has previously been coupled to induction of late markers, which was supported by our findings [29] .
Ingenol Disoxate Stimulates Keratinocyte Pro-inflammatory Cytokine Release and Neutrophil Activation
The recruitment of neutrophil granulocytes into ingenol mebutate treatment fields has been shown to be critical for the eradication of engrafted tumors in a mouse tumor model [30] . Ingenol mebutate is believed to facilitate neutrophil granulocyte tissue infiltration via PKC-dependent mechanisms including [14, 30] . We wanted to test if ingenol disoxate was associated with a similar pro-inflammatory response at nontoxic concentrations. Therefore, we investigated the capacity to stimulate IL-8 release from keratinocytes and found that ingenol disoxate stimulated release of this cytokine with a potency (EC 50 = 3.3 nM) and maximum efficacy comparable to ingenol mebutate (Fig. 7) . A bell-shaped dose-response curve was noted for both compounds peaking between 50 and 300 nM. A similar PKC sensitive biphasic response to ingenol mebutate treatment has previously been related to activation of different PKC isoforms [23] . The relative contribution of various PKC isoforms to the pro-inflammatory cytokine response in this study has not been further explored. Upon tissue extravasation, neutrophil granulocytes can become activated followed by a marked and rapid increase in oxidative metabolism with generation of large amounts of reactive oxygen species (ROS) in a process referred to as the respiratory burst. This response is partly responsible for the cytotoxic actions exerted by this cell type. To monitor the generation of ROS from freshly isolated neutrophil granulocytes, we used the redox-sensitive probe hydroethidine. As shown in Fig. 8 , ingenol disoxate rapidly stimulated the respiratory burst with an EC 50 of 9.6 nM.
These data mirror ingenol mebutate potency and efficacy. The 5-position rearrangement product 8 was approximately tenfold and 56-fold less potent in the IL-8 release and neutrophil activation assays, respectively, whereas the 20-ester 9 was at least 150-fold less potent in either assay (Fig. 7b) .
Ingenol Disoxate Exposure in Human Skin
Biopsies Following Ex Vivo Topical
Application is Highly Different in Epidermis and Dermis
Next, we wanted to relate concentrations sufficient for biological activity to achievable exposure levels in human skin. Ingenol mebutate or ingenol disoxate in chosen. Following 21-h incubation in a Franz diffusion cell set-up, and removal of the stratum corneum using extensive tape-stripping, the epidermal concentration levels averaged 100 lM for either compound (Fig. 9 ).
Dermal exposure levels of ingenol disoxate reached 690 ± 257 nM while dermal ingenol mebutate exposure levels were significantly lower averaging 364 ± 64 nM. Thus, epidermal concentrations were more than 100-fold higher in the epidermis than in the dermis. Three of eighteen dermis samples were not quantified either because exposure levels were below lower LOQ (one ingenol mebutate sample) or because sample vials were destroyed during homogenization (one sample from either ingenol derivative treatment).
Antitumor Efficacy of Ingenol Disoxate in the B16 Melanoma Mouse Model is Superior to Ingenol Mebutate
Ingenol mebutate has been shown to be an effective treatment in mouse models with extending into the subcutis leads to tumor clearance [20, 30] . We have therefore used the B16 melanoma model to compare the in vivo tumor ablating potential of ingenol disoxate and ingenol mebutate using a dose (0.1%) that was previously shown to be efficacious in this model [20] . Our data show that once daily topical application of an equal dose (0.1%) of ingenol disoxate or ingenol mebutate in hydroalcoholic gel for two consecutive days significantly cured or delayed tumor growth in the B16 melanoma mouse model (Fig. 10 ).
In resembling the response seen after treatment of human skin [7] , characterized by the development of edema, erythema and ulceration that peaked after 24 h in all treatment groups. Skin treated with 0.05% compound had slightly higher LSR than after 0.015%. There were no statistically significant differences in composite LSR between the ingenol disoxate and ingenol mebutate treatment groups ( primarily papillomas that finally may progress into SCC. Previous work has shown that field treatment with ingenol mebutate gel after completion of UV irradiation but before development of skin lesions leads to a reduction in tumor incidence [31] . We have used a slightly adapted model to compare the ability of ingenol mebutate and ingenol disoxate to treat UV-induced skin tumors. In our model, we treated individual tumors after they appeared with ingenol mebutate or ingenol disoxate in hydroalcoholic gel for two consecutive days. Ingenol mebutate 0.1% and ingenol disoxate 0.1% showed comparable effect, whereas ingenol mebutate 0.05% displayed a slightly weaker effect (Fig. 11) . None of the tumors in untreated mice regressed spontaneously.
DISCUSSION
The marketed ingenol mebutate gel provides an effective and well-tolerated field treatment of AK characterized by a short treatment regimen and a favorable long-term outcome for the patient. However, the hydroxyl groups in the In our compound screening program, we utilized a simple chemical stability assessment in aqueous buffer (pH 7.4; 16 h, room temperature) as a first tier assay [17, 18] . At these conditions 60% ingenol mebutate and at least 95% ingenol disoxate were recovered. Several studies were conducted on the chemical entities ingenol mebutate and ingenol disoxate in clinically relevant Fig. 11 Comparison of antitumor effects in a UV-induced skin cancer model. Hairless SKH1 mice were irradiated 39 weekly for 10 weeks with a minimally erythemal dose of UV, leading to appearance of skin tumors starting at week 11. Skin tumors were treated topically for two consecutive days with ingenol disoxate or ingenol mebutate in hydroalcoholic gel formulations. Treatment of tumors was done individually starting 1-2 weeks after their appearance. Kaplan-Meyer survival curves are shown with 'survival' time defined as the time until a visible tumor appears within the tattooed area. Due to the skin reaction induced by the compounds it was not possible to assess the tumors until 2 weeks after treatment formulations.
Thus, both compounds formulated in the gel vehicle were stable when stored at 5°C ( with rapid loss of plasma membrane potential and integrity [13, 20] . We demonstrate a similar acute cell death response by ingenol disoxate at micromolar concentrations in epithelial cancer cells but initiated with significantly higher potency relative to ingenol mebutate (Fig. 4) . This effect was observed at concentrations which could be achieved in the epidermal compartment in ex vivo human full thickness skin biopsies 21 h after topical application of a clinically relevant dose (Fig. 9) . We have previously reported a time-dependent decline in ingenol mebutate levels within the epidermal compartment in human skin equivalents indicating keratinocytes might have been exposed to even higher ingenol disoxate levels at earlier time points in this study [13] . Our data suggest that a direct cytotoxic effect on keratinocytes in human skin is feasible using dose strengths similar to the marketed ingenol mebutate gel. [14, 23] . These effects are believed to dominate as the drug penetrates the skin to finally reach nontoxic levels. Our data show that ingenol disoxate potently activated novel and classical PKC isoforms (Table 3) , catalyzed ROS production in activated neutrophils (Fig. 8) and promoted IL-8 release from primary human keratinocytes (Fig. 7) . Most notably, ingenol disoxate showed increased antitumor efficacy in the murine B16 melanoma mouse model compared to ingenol mebutate (Fig. 10a) .
Several explanations can potentially account for this: first, in vitro studies demonstrated that B16 cells were more susceptible to the cytotoxic actions of ingenol disoxate (Fig. 10b) . Second, ingenol disoxate seemed to more efficiently penetrate the skin compared to ingenol mebutate as evidenced by relatively higher ingenol disoxate exposure levels in the dermal compartment of topically treated human skin biopsies (Fig. 9) . The B16 cells reside in the reticular dermis and in the hypodermis, where the exposure level may be borderline cytotoxic; thus a higher exposure of ingenol disoxate may explain the increased tumor efficacy in this model. The difference in penetration was not anticipated based on the Potts and Guy model algorithm for topical drug penetration, which postulates a positive correlation with drug lipophilicity and a negative correlation with molecular size on skin permeability [35] . Thus, the small increase in the measured ingenol disoxate distribution coefficient (logD) was only moderate (3.9 versus 3.5) relative to the slightly smaller sized ingenol mebutate with an expected minimal effect on drug skin permeability.
However, it should be emphasized that it is unclear how well the datasets used for deriving Potts and Guy equations represent the ingenol type of compounds as, for example, steroids have been identified as outliers in the correlation [36] . Third, chemical stability measurements at 37°C in an aqueous buffer (pH 7.4) demonstrated higher relative recoveries of ingenol disoxate relative to ingenol mebutate, i.e., about 98% and 73% ingenol disoxate and 63% and 44% ingenol mebutate after 2 and 24 h, respectively (Fig. 3) . It is unclear to which extent the stability determined in aqueous buffer translates to drug stability within the skin milieu. However, a higher propensity of ingenol mebutate towards progressive rearrangement to the significantly less potent 5-and 20-isomers (6, 7) within the extracellular fluid may offer an alternative explanation for the superior in vivo efficacy of ingenol disoxate.
Although data indicated relatively higher ingenol disoxate skin exposure levels, the magnitude and temporal pattern of the local skin response (LSR) mirrored the effect of ingenol mebutate in the hairless guinea pig; an extensively used model to assess LSRs [37] .
Translation to the clinical setting has subsequently been confirmed by the demonstration of a similar LSR profile of ingenol mebutate and ingenol disoxate at similar dose strengths in patients with AK [38] .
We extended our skin carcinogenesis studies to the hairless and immune-competent SKH1/hr mouse which spontaneously develops tumors following multiple UVR exposures. The model is characterized by the promotion of UV damaged keratinocytes into premalignant exophytic papillomas that finally progress into SCCs breaching the basement membrane and invading the dermis. In the current model, treatment intervention was initiated before papillomas developed into malignant invasive tumors. Our data demonstrate more than 50% tumor clearance for both ingenol disoxate and ingenol mebutate at similar doses, which was largely maintained 5 weeks post treatment (Fig. 11) . Since atypical cells are only located in superficial skin layers, drug exposure levels following either treatment were sufficient to eradicate a large proportion of aberrant cells.
These results support the use of ingenol disoxate in skin malignancies initiated by accumulated UVR exposure. 
CONCLUSIONS
